🔎 Trials Near Me

首页 › 伯基特淋巴瘤 › 密苏里州

密苏里州 的 伯基特淋巴瘤 临床试验

密苏里州 有 8 项针对 伯基特淋巴瘤 的研究正在招募参与者。

密苏里州 的城市

官方研究文本（英文）

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Washington University School of Medicine, St Louis
  • 以及另外 4 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT03739814

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Mercy Hospitals and Clinics, Kansas City
  • Washington University School of Medicine, St Louis
招募中2 期
366 Days – 46 Years · 所有性别 · 更新于 2026年9月28日 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's Mercy Hospitals and Clinics, Kansas City
  • Washington University School of Medicine, St Louis
  • Mercy Hospital Saint Louis, St Louis
招募中2 期
365 Days · 所有性别 · 更新于 2026年9月25日 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Mercy Hospital ( Site 1024), Kansas City
招募中1/2 期
6 Months – 25 Years · 所有性别 · 更新于 2026年9月17日 · NCT06395103

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Washington University School of Medicine, St Louis
  • 以及另外 3 项
招募中3 期
18 至 39 岁 · 所有性别 · 更新于 2026年9月2日 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Mercy Hospitals and Clinics, Kansas City
  • Cardinal Glennon Children's Medical Center, St Louis
  • Washington University School of Medicine, St Louis
  • 以及另外 1 项
招募中2 期
1 至 30 岁 · 所有性别 · 更新于 2026年9月1日 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Missouri Children's Hospital, Columbia
  • Children's Mercy Hospitals and Clinics, Kansas City
  • Cardinal Glennon Children's Medical Center, St Louis
  • 以及另外 2 项
招募中3 期
365 Days – 25 Years · 所有性别 · 更新于 2026年8月25日 · NCT03959085

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Children's Mercy Hospital, Kansas City
招募中2 期
1 至 25 岁 · 所有性别 · 更新于 2025年5月4日 · NCT03509961

数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。